首页> 外文期刊>Thoracic cancer. >Does surgically resected small‐cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?
【24h】

Does surgically resected small‐cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?

机译:手术切除没有淋巴结的小细胞肺癌是否受益于预防性颅辐射?

获取原文
           

摘要

BACKGROUND:It has previously been demonstrated that surgically resected small-cell lung cancer (SCLC) patients could benefit from prophylactic cranial irradiation (PCI). However, PCI in patients without lymph node involvement remains controversial. This study includes a larger sample size to evaluate the benefit of PCI therapy in this specific population.METHODS:The records of surgically resected SCLC patients without lymph node involvement (N0M0) in Shanghai Chest Hospital were retrospectively reviewed.RESULTS:Between January 2006 and May 2017, a total of 146 cases of surgically resected SCLC without lymph node involvement were included. A total of 46 patients received PCI therapy and 100 patients received no therapy. During the observation period, 12.0% (12/100) of the patients who did not receive PCI therapy developed brain metastases while 10.9% (5/46) of patients who received PCI therapy developed brain metastases. With regard to time to recurrence, no significant difference was observed among the groups (P = 0.798). Moreover, there was no significant difference in either the overall survival benefit (hazard ratio [HR] = 0.84, 95% confidence interval [CI]: 0.49-1.45, P = 0.532) or disease-free survival rate (HR = 0.95, 95% CI: 0.52-1.75, P = 0.864).CONCLUSIONS:The evidence obtained does not support PCI therapy in the management of surgically resected SCLC with no lymph node involvement.KEY POINTS:Prophylactic cranial irradiation (PCI) remains controversial for resected small-cell lung cancer (SCLC) without lymph node involvement. In this study, the results indicated that PCI does not reduce the risk of cerebral recurrence of resected p-T1-2N0M0 SCLC. This is the largest sample size study focused on PCI in resected p-T1-2N0M0 SCLC. Future revised versions of the guidelines should address this issue.? 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译:背景:先前已经证明,手术切除的小细胞肺癌(SCLC)患者可以从预防性颅辐射(PCI)中受益。然而,没有淋巴结受累的患者的PCI仍然存在争议。该研究包括更大的样本量,以评估PCI治疗在该特定群体中的益处。方法:上海胸部医院没有淋巴结参与(N0M0)的手术切除的SCLC患者的记录被回顾地审查。结果:2006年1月和5月之间2017年,包括146例外科手术SCLC,没有淋巴结参与。共有46名患者接受PCI治疗,100名患者没有接受治疗。在观察期间,12.0%(12/100)患者未接受PCI治疗的患者开发脑转移,而10.9%(5/46)接受PCI治疗的患者培养了脑转移。关于复发的时间,组中没有观察到显着差异(p = 0.798)。此外,整体存活益处(危害比[HR] = 0.84,95%置信区间[CI]:0.49-1.45,P = 0.532)或无病生存率(HR = 0.95,95 %ci:0.52-1.75,p = 0.864)。结论:获得的证据不支持在手术切除的SCLC管理中,没有淋巴结涉及的证据.KEY点:预防性颅辐射(PCI)仍然存在争议细胞肺癌(SCLC)没有淋巴结受累。在这项研究中,结果表明,PCI不会降低切除的P-T1-2N0M0 SCLC的脑复发风险。这是最大的样本量研究,重点研究了PCI在切除的P-T1-2N0M0 SCLC中。指南的未来修订版本应该解决这个问题。 2020作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号